moexipril (Perdix)

11/01/1995 - "A Study of the Efficacy and Safety of Moexipril in Mild to Moderate Hypertension."
01/01/2005 - "[Moexipril influence on quality of life in postmenopausal women with arterial hypertension]."
01/01/2005 - "Moexipril was given to 35 postmenopausal women with mild and moderate hypertension, menopausal syndrome and decreased bone mineral density. "
01/01/2005 - "[The use of moexipril in postmenopausal women with hypertension and associated changes of bone mineral density]."
01/01/1997 - "24-hour monitoring of arterial pressure was performed before, 3 and 9 weeks after moexipril treatment (daily dose 7.5-15 mg) for mild and moderate hypertension. "

01/01/2005 - "[Assessment of antihypertensive efficacy of moexipril in metabolic syndrome]."
01/01/2006 - "Thus spirapril and moexipril are effective in treatment of hypertension in patients with postmenopausal metabolic syndrome."
01/01/2006 - "Moexipril (7.4-15 mg/day) was given to 34, spirapril (3-6 mg/day) -- to 18 postmenopausal women with hypertension and metabolic syndrome for 16 weeks. "
01/01/2006 - "Patients with postmenopausal metabolic syndrome had elevation of leptin level up to 27.5+/-5.5 pg/ml. Moexipril and spirapril caused lowering of elevated levels of leptin. "
01/01/2006 - "[Comparative efficacy and safety of contemporary Angiotensin converting enzyme inhibitors moexipril and spirapril in women with postmenopausal metabolic syndrome]."

09/01/1998 - "This trial was intended to assess the effect of combined sequential HRT for 25 days on acute changes in arterial distensibility after a single oral dose of 15 mg moexipril hydrochloride in postmenopausal women with borderline to mild essential hypertension. "
01/01/2005 - "Moexipril 15 mg once daily administered for 24 weeks resulted in a significant reversal of LVH in patients with essential hypertension. "
09/01/1998 - "Arterial function improves after acute administration of 15 mg moexipril in postmenopausal women with mild to moderate essential hypertension. "
06/01/1998 - "Once daily moexipril is a useful agent for the treatment of essential hypertension, which compares well with currently available options in terms of clinical efficacy and tolerability. "
06/01/1998 - "Once daily administration of moexipril 7.5 or 15 mg effectively reduces blood pressure in patients with essential hypertension (including the elderly and postmenopausal women with this condition). "

01/01/2006 - "The study of efficacy of moexipril in chronic heart failure in women is able to broaden indications to the use of this drug."
01/01/2005 - "[Hemodynamic and anti-ischemic effects of moexipril in patients having postinfarction heart dysfunction and moderate left ventricular heart failure]."
01/01/2005 - "The purpose of the study was to evaluate hemodynamic and anti-ischemic effects of moexipril in patients with postinfarction left ventricular dysfunction (PL VD) and moderate left ventricular heart failure (NYHA functional class II-III). "
01/01/2005 - "The results of the 4-week moexipril administration demonstrate hemodynamic and anti-ischemic effects of the new ACF inhibitor, its positive influence on transcapillary oxygen exchange and MC in patients with PLVD, associated with NYHA functional class II-III heart failure."

02/01/2010 - "Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid."
02/01/2010 - "We evaluated the safety and efficacy of moexipril, an angiotensin-converting enzyme inhibitor, in patients with primary biliary cirrhosis (PBC) who have had a suboptimal response to ursodeoxycholic acid (UDCA). "